Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma

Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma

Hypofractionated radiotherapy (HypoRT) has recently been implemented in patients with glioblastoma (GBM) receiving concurrent temozolomide. Lymphopenia during treatment (LDT) is considered an important prognostic factor of clinical outcomes for GBM. We aimed to investigate the outcomes of HypoRT. Am...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Yonsei medical journal 2023, 64(2), , pp.94-103
Hauptverfasser: Kim, Nalee, Lim, Do Hoon, Choi, Jung Won, Lee, Jung-Il, Kong, Doo-Sik, Seol, Ho Jun, Nam, Do-Hyun
Format: Artikel
Sprache:eng
Schlagworte:
Brain - pathology
Brain Neoplasms - drug therapy
Brain Neoplasms - pathology
Brain Neoplasms - radiotherapy
Chemoradiotherapy - adverse effects
Glioblastoma - drug therapy
Glioblastoma - radiotherapy
Humans
Original
Radiation Dose Hypofractionation
Temozolomide - therapeutic use
의학일반
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hypofractionated radiotherapy (HypoRT) has recently been implemented in patients with glioblastoma (GBM) receiving concurrent temozolomide. Lymphopenia during treatment (LDT) is considered an important prognostic factor of clinical outcomes for GBM. We aimed to investigate the outcomes of HypoRT. Among 223 patients with GBM, 145 and 78 were treated with conventionally fractionated RT (ConvRT, 60 Gy in 30 fractions) and HypoRT (58.5 Gy in 25 fractions), respectively. To balance characteristics between the two groups, propensity score matching (PSM) was performed. Patients in the HypoRT group were older and had smaller tumors than those in the ConvRT group (
ISSN:0513-5796
1976-2437
DOI:10.3349/ymj.2022.0352